新抗原癌症疫苗市場(2024-2031)、方法、治療線、類型、用途、治療策略、分析/國家預測
市場調查報告書
商品編碼
1057019

新抗原癌症疫苗市場(2024-2031)、方法、治療線、類型、用途、治療策略、分析/國家預測

Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis - Analysis and Forecast, 2024-2031

出版日期: | 出版商: BIS Research | 英文 199 Pages | 商品交期: 1-5個工作天內

價格

全球新抗原癌症疫苗市場預計在預測期內將以 77.73% 的顯著複合年增長率增長,從 2024 年的 3550 萬美元增長到 2031 年的 19.885 億美元。

新抗原癌症疫苗市場的增長主要是由於癌症患病率的增加,在個體層面調整患者治療的個體化醫療的引入增加,以及需要大規模的外部資金來進行研發出來。它正在被引進等因素推動。另一方面,個性化癌症疫苗的高成本、臨床開發的障礙、保險公司的不確定性和基於績效的定價是進一步市場增長的挑戰。

本報告調查了全球新抗原癌症疫苗市場、市場和產品概況、市場影響因素分析、監管環境、專利趨勢、產品管線、市場規模趨勢和預測、產品類型。產品、新疫苗類型、治療線、治療部門、地區/主要國家、競爭環境、主要公司概況等。

目錄

第1章產品定義

第2章調查範圍

第3章調查方法

第4章癌症免疫治療中的新抗原癌症疫苗:概述

  • 癌抗原
  • 靶向癌症新抗原:腫瘤學的下一波創新浪潮?
  • 新抗原癌症疫苗的作用機制
  • 新抗原癌症疫苗類型:按產品類型
  • 新抗原癌症疫苗市場類型:按新疫苗類型(生物平台)
  • 新抗原癌症疫苗類型:按遞送類型
  • 新抗原預測軟件
  • 新抗原癌症疫苗藥物
  • 未來展望

第5章工業考慮

  • 新抗原癌症疫苗的監管途徑概述
  • 監管問題
  • 有效的監管策略
  • 專利情況

第 6 章 COVID-19 對全球新抗原癌症疫苗市場的影響

第7章市場動態

  • 概覽
  • 新興和當前市場趨勢
  • 市場促進因素
  • 市場製約因素
  • 市場機會

第8章管道情況

  • 新抗原癌症疫苗
  • 臨床試驗熱圖
  • 管道分析

第 9 章全球新抗原癌症疫苗市場:按產品類型

  • 個性化新抗原癌症疫苗
  • 現成的新抗原癌症疫苗

第 10 章全球新抗原癌症疫苗市場:按管道產品分類

  • 特多皮
  • Allovax
  • DC(樹突狀細胞)疫苗
  • ADXS-Neo
  • GEN-009
  • RG6180

第 11 章全球新抗原癌症疫苗市場:按新疫苗類型

  • 核酸(DNA/RNA疫苗)
    • DNA疫苗
    • RNA疫苗
  • □疫苗
  • 樹突狀細胞疫苗

第 12 章全球新抗原癌症疫苗市場:按治療線

  • 一線新疫苗方案
  • 二線新疫苗方案
  • 其他萊茵新疫苗方案

第 13 章全球新抗原癌症疫苗市場:按治療部門

  • 黑色素瘤
  • 肺癌
  • 泌尿系癌
  • 肝癌
  • 頭頸癌
  • 血液和骨髓瘤

第 14 章全球新抗原癌症疫苗市場:按地區分列

  • 概覽
  • 北美
  • 歐洲
  • 亞太地區和中東

第15章競爭態勢

  • 概覽
  • 主要發展/戰略

第 16 章公司簡介

  • Moderna Therapeutics
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca plc
  • Agenus
  • OSE Immunotherapeutics
  • Advaxis
  • Medigene
  • Neon Therapeutics
  • Genocea Biosciences
  • Immunovative Therapies
  • Gritstone Oncology
  • Nouscom
  • NantBioScience
  • Immunovaccine
  • BioLineRx
  • Geneos Therapeutics
Product Code: BHL0787SB

“Global Neoantigen Cancer Vaccine Market to Reach $1,988.5 Million by 2031.”

Market Report Coverage - Neoantigen Cancer Vaccine

Market Segmentation

  • Product Type - Personalized and Off-the-Shelf
  • Type of Neovaccine - Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine
  • Therapeutic Specialty - Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer
  • Line of Therapy - First Line, Second Line, and Later Lines

Regional Segmentation

  • North America - U.S. and Canada
  • Europe - Germany, U.K., France, Italy, and Spain
  • Asia-Pacific and Middle East - China, Australia, Japan, South Korea, and Israel

Market Growth Drivers

  • Increasing Global Prevalence of Cancer
  • Increase in Adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level
  • Significant External Funding for Executing Research and Development Exercise

Market Challenges

  • Higher Cost of Personalized Cancer Vaccines
  • Hurdles in Clinical Development and Optimization Process
  • Uncertain Reimbursement Scenario
  • Payer Uncertainty and Outcome-Based Pricing
  • High Capital Requirement Hampering the Expansion of Global Reach

Market Opportunities

  • Treatment Gaps
  • Reduced Turnaround Time and Cost
  • Partnerships and Collaboration between Various Healthcare Stakeholders
  • Data Analytics

Key Companies Profiled

Moderna Therapeutics, F. Hoffmann-La Roche Ltd, AstraZeneca plc, Agenus, OSE Immunotherapeutics, Advaxis, Medigene, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies, Gritstone Oncology, Nouscom, NantBioScience, Immunovaccine, BioLineRx, Geneos Therapeutics.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?
  • What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?
  • What key development strategies are implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?
  • How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of:
    • Product Type (Personalized and Off-the-Shelf),
    • Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine)
    • Line of Therapy (First Line, Second Line, and Later Lines)
    • Region, including North America, Europe, Asia-Pacific and Middle East
  • Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the current treatment gaps, and how neovaccines are expected to fill these gaps?
  • What are the unmet needs in the global neoantigen cancer vaccine market?

Market Overview

The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.

The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient's treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.

Expert Quote on the Neoantigen Cancer Vaccine Market

"The real issues with neovaccines are higher cost, turn-around times, and limited efficacy. The cost and time to manufacture have come down in the last four years, and as technology improves, it will come down more."

The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape.

The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub segment and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.

Pipeline Segmentation

  • The emerging neoantigen cancer vaccines are segmented based on product type into personalized and off-the-shelf neovaccines.
  • The emerging neoantigen cancer vaccines are segmented based on disease/application into lung cancer, urinary system cancer, melanoma, liver cancer, head and neck cancer, and blood and bone marrow cancer.
  • The emerging neoantigen cancer vaccines are segmented based on type of neovaccine into nucleic acid vaccine, peptide vaccine, and dendritic cell vaccine.
  • The emerging neoantigen cancer vaccines are segmented based on line of therapy into first, second, and later lines therapy.
  • The emerging neoantigen cancer vaccines are segmented based on development phase into Phase I, II, and III.
  • The emerging neoantigen cancer vaccines are segmented on the basis of route-of-administration into intradermal, subcutaneous, and intramuscular administrations.

Table of Contents

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Primary Data Sources
    • 3.1.1 Secondary Data Sources
  • 3.2 Market Estimation Model
    • 3.2.1 Factors for Data Prediction and Modelling
    • 3.2.2 Assumptions and Limitations

4 Neoantigen Cancer Vaccine in Cancer Immunotherapy: Overview

  • 4.1 Introduction
  • 4.2 Cancer Antigens
  • 4.3 Targeting Cancer Neoantigen: A Next Wave of Innovation in Oncology?
  • 4.4 Neoantigen Cancer Vaccine Mechanism of Action
  • 4.5 Types of Neoantigen Cancer Vaccine (by Product Type)
    • 4.5.1 Personalized Cancer Vaccine
    • 4.5.2 Off-the-Shelf Neoantigen Cancer Vaccine
  • 4.6 Types of Neoantigen Cancer Vaccine Market (by Type of Neovaccine (Biological Platform))
    • 4.6.1 Nucleic Acid/DNA/mRNA Vaccine
    • 4.6.2 Peptide Vaccine
    • 4.6.3 Dendritic Cell-Based Vaccine
  • 4.7 Types of Neoantigen Cancer Vaccine (by Type of Delivery)
    • 4.7.1 Lipid-Based Delivery Approaches
      • 4.7.1.1 Peptide (SLP) Mediate Vaccine Delivery in Conjunction with an Adjuvant
      • 4.7.1.2 Sequential Immunization of Viral Prime and RNA Boost
    • 4.7.2 Direct Injection of Unformulated mRNA Vaccines Encoding Neoepitopes
    • 4.7.3 Other Approaches
  • 4.8 Prediction Software for Neoantigens
    • 4.8.1 Limitations of Neoantigen Prediction Process
  • 4.9 Limitations of Neoantigen Cancer Vaccine
    • 4.9.1 Lower Tumor Mutational Burden
    • 4.9.2 Neoantigens Maturity
  • 4.1 Future Prospects
    • 4.10.1 Multi-Epitope Vaccination
    • 4.10.2 Combinatorial Regimen with Targeted Therapies
    • 4.10.3 Combinatorial Regimen with Conventional Cancer Therapies

5 Industry Insights

  • 5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccine
    • 5.1.1 U.S. FDA Guidelines for Biologics License Application (BLA) Submission
    • 5.1.2 European Medicine Agency (EMA) Biologics License Application Process
      • 5.1.2.1 Centralized Procedure
      • 5.1.2.2 Decentralized Procedure
      • 5.1.2.3 Mutual-Recognition Procedure
  • 5.2 Regulatory Challenges
  • 5.3 Successful Regulatory Strategies
  • 5.4 Patent Landscape

6 Impact of COVID-19 on the Global Neoantigen Cancer Vaccine Market

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Emerging and Current Market Trends
  • 7.3 Market Drivers
    • 7.3.1 Increasing Global Prevalence of Cancer
    • 7.3.2 Increase in Adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level
    • 7.3.3 Significant External Funding for Executing Research and Development Exercise
  • 7.4 Market Restraints
    • 7.4.1 Higher Cost of Personalized Cancer Vaccines
    • 7.4.2 Hurdles in Clinical Development and Optimization Process
    • 7.4.3 Uncertain Reimbursement Scenario
    • 7.4.4 Payer Uncertainty and Outcome-Based Pricing
    • 7.4.5 High Capital Requirement Hampering the Expansion of Global Reach
  • 7.5 Market Opportunities
    • 7.5.1 Treatment Gaps
    • 7.5.2 Reduced Turnaround Time and Cost
    • 7.5.3 Partnerships and Collaboration between Various Healthcare Stakeholders
    • 7.5.4 Data Analytics

8 Pipeline Landscape

  • 8.1 Emerging Neoantigen Cancer Vaccine
  • 8.2 Clinical Trials Heat Map
  • 8.3 Pipeline Analysis
    • 8.3.1 By Development Phase
    • 8.3.2 By Type of Therapy
    • 8.3.3 By Product Type
    • 8.3.4 By Treatment Strategy
    • 8.3.5 By Type of Neovaccine
    • 8.3.6 By Delivery Approach
    • 8.3.7 By Line of Therapy
    • 8.3.8 By Therapeutic Specialty
    • 8.3.9 By Route of Administration
    • 8.3.10 By Core Product Status
    • 8.3.11 By Neoantigen Payload

9 Global Neoantigen Cancer Vaccine Market (by Product Type)

  • 9.1 Personalized Neoantigen Cancer Vaccine
  • 9.2 Off-the-Shelf Neoantigen Cancer Vaccine

10 Global Neoantigen Cancer Vaccine Market (by Pipeline Product)

  • 10.1 Tedopi
  • 10.2 Allovax
  • 10.3 DC (Dendritic Cells) Vaccine
  • 10.4 ADXS-Neo
  • 10.5 GEN-009
  • 10.6 RG6180

11 Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine)

  • 11.1 Nucleic Acid (DNA/RNA Vaccine)
    • 11.1.1 DNA Vaccine
    • 11.1.2 RNA Vaccine
  • 11.2 Peptide Vaccines
  • 11.3 Dendritic Cell-Based Vaccine

12 Global Neoantigen Cancer Vaccine Market (by Line of Therapy)

  • 12.1 First Line Neovaccine Regimens
  • 12.2 Second Line Neovaccine Regimens
  • 12.3 Later Lines Neovaccine Regimens

13 Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), 2024-2031

  • 13.1 Melanoma
  • 13.2 Lung Cancer
  • 13.3 Urinary System Cancer
  • 13.4 Liver Cancer
  • 13.5 Head and Neck Cancer
  • 13.6 Blood and Bone Marrow Cancer

14 Global Neoantigen Cancer Vaccine Market (by Region)

  • 14.1 Overview
  • 14.2 North America
  • 14.3 U.S.
    • 14.3.1 Market Size and Forecast
  • 14.4 Canada
    • 14.4.1 Market Size and Forecast
  • 14.5 Europe
    • 14.5.1 Germany
      • 14.5.1.1 Market Size and Forecast
    • 14.5.2 France
      • 14.5.2.1 Market Size and Forecast
    • 14.5.3 U.K.
      • 14.5.3.1 Market Size and Forecast
    • 14.5.4 Italy
      • 14.5.4.1 Market Size and Forecast
    • 14.5.5 Spain
      • 14.5.5.1 Market Size and Forecast
  • 14.6 Asia-Pacific and Middle East
    • 14.6.1 Japan
      • 14.6.1.1 Market Size and Forecast
    • 14.6.2 China
      • 14.6.2.1 Market Size and Forecast
    • 14.6.3 Australia
      • 14.6.3.1 Market Size and Forecast
    • 14.6.4 South Korea
      • 14.6.4.1 Market Size and Forecast
    • 14.6.5 Israel
      • 14.6.5.1 Market Size and Forecast

15 Competitive Landscape

  • 15.1 Overview
  • 15.2 Key Developments and Strategies
    • 15.2.1 Partnerships and Alliances
    • 15.2.2 Business Expansions
    • 15.2.3 Merger and Acquisition Activities
    • 15.2.4 Product Approvals
    • 15.2.5 Financing Activities
    • 15.2.6 Funding Activities
    • 15.2.7 Regulatory and Legal Activities

16 Company Profiles

  • 16.1 Moderna Therapeutics
    • 16.1.1 Company Overview
    • 16.1.2 Role of Moderna Therapeutics in the Global Neoantigen Cancer Vaccine Market
    • 16.1.3 Technology and Capabilities
    • 16.1.4 Financials
    • 16.1.5 Key Insights about Financial Health of the Company
    • 16.1.6 SWOT Analysis:
  • 16.2 F. Hoffmann-La Roche Ltd
    • 16.2.1 Company Overview
    • 16.2.2 Role of F. Hoffmann-La Roche Ltd in the Global Neoantigen Cancer Vaccine Market
    • 16.2.3 Technology and Capabilities
      • 16.2.3.1 Technology Platform
      • 16.2.3.2 Manufacturing
    • 16.2.4 Financials
    • 16.2.5 Key Insights about Financial Health of the Company
    • 16.2.6 SWOT Analysis:
  • 16.3 AstraZeneca plc
    • 16.3.1 Company Overview
    • 16.3.2 Role of AstraZeneca plc in the Global Neoantigen Cancer Vaccine Market
    • 16.3.3 Financials
    • 16.3.4 Key Insights about Financial Health of the Company
    • 16.3.5 SWOT Analysis:
  • 16.4 Agenus
    • 16.4.1 Company Overview
    • 16.4.2 Role of Agenus in the Global Neoantigen Cancer Vaccine Market
    • 16.4.3 Technology and Capabilities
      • 16.4.3.1 Technology Platforms
      • 16.4.3.2 Manufacturing
      • 16.4.3.3 Adjuvant
    • 16.4.4 Financials
    • 16.4.5 Key Insights about Financial Health of the Company
    • 16.4.6 SWOT Analysis:
  • 16.5 OSE Immunotherapeutics
    • 16.5.1 Company Overview
    • 16.5.2 Role of OSE Immunotherapeutics in the Global Neoantigen Cancer Vaccine Market
    • 16.5.3 Technology and Capabilities
      • 16.5.3.1 Technology Platforms
      • 16.5.3.2 Manufacturing
    • 16.5.4 Financials
    • 16.5.5 Key Insights about Financial Health of the Company
    • 16.5.6 SWOT Analysis:
  • 16.6 Advaxis
    • 16.6.1 Company Overview
    • 16.6.2 Role of Advaxis in the Global Neoantigen Cancer Vaccine Market
    • 16.6.3 Technology and Capabilities
      • 16.6.3.1 Technology platform
      • 16.6.3.2 Manufacturing
    • 16.6.4 Financials
    • 16.6.5 Key Insights about Financial Health of the Company
    • 16.6.6 SWOT Analysis:
  • 16.7 Medigene
    • 16.7.1 Company Overview
    • 16.7.2 Role of Medigene in the Global Neoantigen Cancer Vaccine Market
    • 16.7.3 Technology and Capabilities
      • 16.7.3.1 Technology Platform
      • 16.7.3.2 Manufacturing
    • 16.7.4 Financials
    • 16.7.5 Key Insights about Financial Health of the Company
    • 16.7.6 SWOT Analysis:
  • 16.8 Neon Therapeutics (Acquired by BioNTech SE)
    • 16.8.1 Company Overview
    • 16.8.2 Role of Neon Therapeutics (Acquired by BioNTech SE) in the Global Neoantigen Cancer Vaccine Market
    • 16.8.3 Technology and Capabilities
      • 16.8.3.1 Technology Platforms
      • 16.8.3.2 Manufacturing
    • 16.8.4 SWOT Analysis:
  • 16.9 Genocea Biosciences
    • 16.9.1 Company Overview
    • 16.9.2 Role of Genocea Biosciences in the Global Neoantigen Cancer Vaccine Market
    • 16.9.3 Technology and Capabilities
      • 16.9.3.1 Technology Platform
      • 16.9.3.2 Manufacturing Capabilities
    • 16.9.4 SWOT Analysis:
  • 16.1 Immunovative Therapies
    • 16.10.1 Company Overview
    • 16.10.2 Role of Immunovative Therapies in the Global Neoantigen Cancer Vaccine Market
    • 16.10.3 Technology and Capabilities
      • 16.10.3.1 Technology Platform
      • 16.10.3.2 Manufacturing
    • 16.10.4 SWOT Analysis:
  • 16.11 Gritstone Oncology
    • 16.11.1 Company Overview
    • 16.11.2 Role of Gritstone Oncology in the Global Neoantigen Cancer Vaccine Market
    • 16.11.3 Technology and Capabilities
      • 16.11.3.1 Technology Platform
      • 16.11.3.2 Manufacturing
    • 16.11.4 SWOT Analysis:
  • 16.12 Nouscom
    • 16.12.1 Company Overview
    • 16.12.2 Role of Nouscom in the Global Neoantigen Cancer Vaccine Market
    • 16.12.3 Technology and Capabilities
      • 16.12.3.1 Technology Platform
      • 16.12.3.2 Manufacturing
    • 16.12.4 SWOT Analysis:
  • 16.13 NantBioScience
    • 16.13.1 Company Overview
    • 16.13.2 Role of NantBioScience in the Global Neoantigen Cancer Vaccine Market
    • 16.13.3 SWOT Analysis:
  • 16.14 Immunovaccine
    • 16.14.1 Company Overview
    • 16.14.2 Role of Immunovaccine in the Global Neoantigen Cancer Vaccine Market
    • 16.14.3 SWOT Analysis:
  • 16.15 BioLineRx
    • 16.15.1 Company Overview
    • 16.15.2 Role of BioLineRx in the Global Neoantigen Cancer Vaccine Market
    • 16.15.3 SWOT Analysis:
  • 16.16 Geneos Therapeutics
    • 16.16.1 Company Overview
    • 16.16.2 Role of Geneos Therapeutics in the Global Neoantigen Cancer Vaccine Market
    • 16.16.3 SWOT Analysis:

List of Figures

  • Figure 1: Impact Analysis of Market Drivers and Market Restraints on the Global Neoantigen Cancer Vaccine Market
  • Figure 2: Global Neoantigen Cancer Vaccine Market Size (by Product Type), $Million, 2024 and 2031
  • Figure 3: Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024 and 2031
  • Figure 4: Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024 and 2031
  • Figure 5: Global Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024 and 2031
  • Figure 6: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024 and 2031
  • Figure 7: Global Neoantigen Cancer Vaccine Market Segmentation
  • Figure 8: Global Neoantigen Cancer Vaccine Market: Existing Pipeline Segmentation
  • Figure 9: Global Neoantigen Cancer Vaccine Market Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Step by Step Approach
  • Figure 13: Step by Step Process for Neoantigen Vaccine Development
  • Figure 14: Type of Cancer Antigens
  • Figure 15: Specialized Therapies Segmentation in the U.S.
  • Figure 16: Neoantigen Cancer Vaccine Mechanism of Action
  • Figure 17: Factors Affecting Neoantigen Prediction Process
  • Figure 18: Future Prospects of Neovaccines
  • Figure 19: U.S. FDA Review Timeline
  • Figure 20: EMA Review Timeline
  • Figure 21: Share of Patents (by Ownership), 2016-2019
  • Figure 22: Number of Deaths Due to Different Cancer Types, Million, 2020
  • Figure 23: Global Cancer Incidence, Million, 2018
  • Figure 24: Neovaccines Funding and Expansion Activities Breakout, January 2016-September 2019
  • Figure 25: Overall Financing Raised by Emerging Neovaccine Companies, $Million, January 2016-September 2019
  • Figure 26: Overview of Reimbursement Policies in Europe
  • Figure 27: Market Opportunities
  • Figure 28: Key Neoantigen Cancer Vaccine in Clinical Development Phase I, II and III, 2021
  • Figure 29: Neoantigen Cancer Vaccine: Clinical Trials Heat Map
  • Figure 30: Neoantigen Cancer Vaccine: Breakdown of Pipeline (by Development Phase), 2021
  • Figure 31: Neoantigen Cancer Vaccine (by Type of Therapy)
  • Figure 32: Neoantigen Cancer Vaccine (by Product Type)
  • Figure 33: Neoantigen Cancer Vaccine (by Treatment Strategy)
  • Figure 34: Neoantigen Cancer Vaccine (by Type of Neovaccine (Biological Platform))
  • Figure 35: Neoantigen Cancer Vaccine (by Delivery Approach)
  • Figure 36: Neoantigen Cancer Vaccine, by Line of Therapy
  • Figure 37: Number of Neoantigen Cancer Vaccine (by Oncology Speciality)
  • Figure 38: Neoantigen Cancer Vaccine (by Route of Administration)
  • Figure 39: Neoantigen Cancer Vaccine (by Core Product Status)
  • Figure 40: Neoantigen Cancer Vaccine (by Neoantigen Payload)
  • Figure 41: Revenue Contribution of Different Segments (by Product Type), $Million, 2024 and 2031
  • Figure 42: Personalized Neoantigen Cancer Vaccine Market (by Product Type), $Million, 2024-2031
  • Figure 43: Off-the-Shelf Neoantigen Cancer Vaccine Market (by Product Type), $Million, 2024-2031
  • Figure 44: Revenue Contribution of Different Segments (by Pipeline), $Million, 2024 and 2031
  • Figure 45: Tedopi-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
  • Figure 46: Allovax-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
  • Figure 47: DC (Dendritic Cells) Vaccine-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
  • Figure 48: ADXS-Neo-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
  • Figure 49: GEN-009-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
  • Figure 50: RG6180-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
  • Figure 51: Revenue Contribution of Different Segments (by Type of Neovaccine), $Million, 2024 and 2031
  • Figure 52: DNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), $Million, 2024-2031
  • Figure 53: RNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), $Million, 2024-2031
  • Figure 54: Peptide Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024-2031
  • Figure 55: Dendritic Cell-Based Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024-2031
  • Figure 56: Revenue Contribution of Different Segments (by Line of Therapy), $Million, 2024 and 2031
  • Figure 57: First Line Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031
  • Figure 58: Second Line Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031
  • Figure 59: Later Lines Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031
  • Figure 60: Melanoma Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
  • Figure 61: Lung Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
  • Figure 62: Urinary System Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
  • Figure 63: Liver Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
  • Figure 64: Head and Neck Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
  • Figure 65: Blood and Bone Marrow Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
  • Figure 66: Global Neoantigen Cancer Vaccine Market (by Region)
  • Figure 67: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024 and 2031
  • Figure 68: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024-2031
  • Figure 69: North America: Market Dynamics
  • Figure 70: North America Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 71: North America Neoantigen Cancer Vaccine Revenue Contribution (by Country), $Million, 2024 and 2031
  • Figure 72: Projections of the Older Adult Population in the U.S., Million, 2016-2060
  • Figure 73: U.S. Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 74: Canada Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 75: Europe: Market Dynamics
  • Figure 76: Europe Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 77: Europe Neoantigen Cancer Vaccine Revenue Contribution (by Country), $Million, 2024 and 2031
  • Figure 78: Germany Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 79: France Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 80: U.K. Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 81: Italy Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 82: Spain Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 83: Asia-Pacific: Market Dynamics
  • Figure 84: Asia-Pacific Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 85: Asia-Pacific and Middle East Revenue Contributions of Various Countries, $Million, 2024 and 2031
  • Figure 86: Japan Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 87: China Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 88: Australia Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 89: South Korea Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 90: Israel Neoantigen Cancer Vaccine Market, $Million, 2024-2031
  • Figure 91: Share of Key Developments and Strategies, January 2016-November 2021
  • Figure 92: Partnerships and Alliances (by Company), January 2016-November 2021
  • Figure 93: Business Expansions (by Company), January 2016-November 2021
  • Figure 94: Merger and Acquisition Activities (by Company), January 2016-November 2021
  • Figure 95: Product Approvals (by Company), January 2016-November 2021
  • Figure 96: Financing Activities (by Company), January 2016-November 2021
  • Figure 97: Funding Activities (by Company), January 2016-November 2021
  • Figure 98: Regulatory and Legal Activities (by Company), January 2016-November 2021
  • Figure 99: Moderna Therapeutics: Technology and Capabilities
  • Figure 100: Moderna Therapeutics: Therapeutic Focus Segmentation
  • Figure 101: Moderna Therapeutics: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 102: Moderna Therapeutics.: R&D Expenditure, $Million, 2018-2020
  • Figure 103: Moderna Therapeutics: SWOT Analysis
  • Figure 104: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 105: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2018-2020
  • Figure 106: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2018-2020
  • Figure 107: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2018-2020
  • Figure 108: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2018-2020
  • Figure 109: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 110: AstraZeneca plc: Therapeutic Focus Segmentation
  • Figure 111: AstraZeneca plc: Overall Financials/Revenue, $Billion, 2018-2020
  • Figure 112: AstraZeneca plc: Net Revenue (by Region), $Billion, 2018-2020
  • Figure 113: AstraZeneca plc: R&D Expenditure, $Billion, 2018-2020
  • Figure 114: AstraZeneca plc: SWOT Analysis
  • Figure 115: Agenus: Technology and Capabilities (as Per Type of Product)
  • Figure 116: Agenus: Therapeutic Focus Segmentation
  • Figure 117: Agenus: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 118: Agenus: R&D Expenditure, $Million, 2018-2020
  • Figure 119: Agenus: SWOT Analysis
  • Figure 120: OSE Immunotherapeutics: Therapeutic Focus Segmentation
  • Figure 121: OSE Immunotherapeutics: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 122: OSE Immunotherapeutics: R&D Expenditure, $Million, 2016-2018
  • Figure 123: OSE Immunotherapeutics: SWOT Analysis
  • Figure 124: Advaxis: Therapeutic Focus Segmentation
  • Figure 125: Advaxis: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 126: Advaxis: R&D Expenditure, $Million, 2018-2020
  • Figure 127: Advaxis: SWOT Analysis
  • Figure 128: Medigene: Therapeutic Focus Segmentation
  • Figure 129: Medigene: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 130: Medigene: R&D Expenditure, $Million, 2018-2020
  • Figure 131: Medigene: SWOT Analysis
  • Figure 132: Neon Therapeutics: Therapeutic Focus Segmentation (Available From FY2019)
  • Figure 133: Neon Therapeutics (Acquired by BioNTech): SWOT Analysis
  • Figure 134: Genocea Biosciences: Therapeutic Focus Segmentation
  • Figure 135: Genocea Biosciences: SWOT Analysis
  • Figure 136: Immunovative Therapies: SWOT Analysis
  • Figure 137: Gritstone Oncology: Therapeutic Focus Segmentation
  • Figure 138: Gritstone Oncology: SWOT Analysis
  • Figure 139: Nouscom: Therapeutic Focus Segmentation (Available from FY2019)
  • Figure 140: Nouscom: SWOT Analysis
  • Figure 141: NantBioScience: SWOT Analysis
  • Figure 142: Immunovaccine: SWOT Analysis
  • Figure 143: BioLineRx: SWOT Analysis
  • Figure 144: Geneos Therapeutics: SWOT Analysis

List of Tables

  • Table 1: Implications of Personalized Cancer Vaccines (PCVs)
  • Table 2: Implications of Off-the-Shelf Neoantigen Cancer Vaccine
  • Table 3: Implications of DNA and RNA Vaccines
  • Table 4: Implications of Peptide Vaccine
  • Table 5: Implications of Dendritic Cell Vaccine
  • Table 6: Prediction Software Utilized by Various Companies
  • Table 7: Neoantigen Cancer Vaccines Patent Landscape, by 2019
  • Table 8: Neoantigen Cancer Vaccine (by Type of Therapy)
  • Table 9: Neoantigen Cancer Vaccine (by Line of Therapy)
  • Table 10: Neoantigen Cancer Vaccine (by Route of Administration)
  • Table 11: Neoantigen Cancer Vaccine (by Core Product Type (Licensed Products/ Technology Only))
  • Table 12: Neoantigen Cancer Vaccine (by Neoantigen Payload)
  • Table 13: Neoantigen Cancer Vaccine for Melanoma: Pipeline Products
  • Table 14: Neoantigen Cancer Vaccine for Lung Cancer: Pipeline Products
  • Table 15: Neoantigen Cancer Vaccine for Urinary Cancer: Pipeline Products
  • Table 16: Neoantigen Cancer Vaccine for Head and Neck Cancer: Pipeline Products
  • Table 17: Neoantigen Cancer Vaccine for Blood and Bone Marrow Cancer: Pipeline Products